VIVUS, Inc. : New Article Discusses Treatment Options for Weight Management in People With Type 2 Diabetes (4-Traders)
VIVUS, Inc. (NASDAQ:VVUS) today announced that a review article has been published online in TheJournal of Diabetes and Its Complications examining the importance of weight management in the treatment of type 2 diabetes. The article reviews treatment options, including lifestyle interventions, pharmacotherapy and surgery, citing Qsymia® (phentermine and topiramate extended-release) capsules CIV as a treatment option. …According to the article, studies have shown that moderate weight loss in obese patients with type 2 diabetes mellitus (T2DM) can lead to reductions in cardiometabolic risk factors such as dyslipidemia and hypertension and can have a substantial impact on mortality.
Weight-loss drug goes on sale Tuesday (UTSandiego)
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’ highly anticipated weight-loss drug, Belviq, will go on sale on Tuesday, the San Diego company announced today. …However, Qsymia’s head start hasn’t closed the door on Belviq. Sales of Qsymia have been modest to slow, according to quarterly reports from VIVUS, Inc. (NASDAQ:VVUS). In the quarter ended March 31, VIVUS, Inc. (NASDAQ:VVUS) reported Qsymia net revenue of $4.1 million. On the whole, the company had a net loss of $53.6 million, or 53 cents per share. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) lost $18.9 million, or 9 cents per share, in that quarter.
Sarissa’s Stake in Vivus, Inc. (VVUS) Points to Renewed Interest in the Company (InsiderMonkey)
Noted hedge fund Sarissa Capital Management recently disclosed a stake of nearly 2% in promising biotechnology firm VIVUS, Inc. (NASDAQ:VVUS). Although it had been widely anticipated by keen-eyed market observers, this event nevertheless highlighted the renewed interest in VIVUS, Inc. (NASDAQ:VVUS)’ long-term prospects. Like many small biotech firms that focus on developing and marketing experimental or advanced drugs, VIVUS has had a volatile run over the past few years. After several quarters in the doghouse, VIVUS, Inc. (NASDAQ:VVUS) may finally be benefiting from a promising pipeline and could even become an acquisition target at some point in the future.
VIVUS (VVUS) Files Proxy Materials for FY13 Shareholders Meeting (StreetInsider)
VIVUS, Inc. (NASDAQ:VVUS) announced that it has filed its definitive proxy materials in connection with the Company’s 2013 Annual Meeting of Stockholders, to be held on July 15, 2013, with the Securities and Exchange Commission (“SEC”). VIVUS stockholders of record at the close of business on May 31, 2013 are entitled to vote at the 2013 Annual Meeting. The VIVUS, Inc. (NASDAQ:VVUS) Board of Directors unanimously recommends that stockholders vote “FOR” all of the Company’s experienced and highly qualified directors – Leland F. Wilson; Peter Y. Tam; Mark B. Logan; J. Martin Carroll; Charles J. Casamento; Ernest Mario, Ph.D.; Jorge Plutzky, M.D.; Linda M. Dairiki Shortliffe, M.D.; and Robert N. Wilson – on the GOLD proxy card. Stockholders are encouraged to vote today by Internet, by telephone or by signing, dating and returning the GOLD proxy card.